Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

TMates Weightloss Semaglutide reviews reveal how users are losing weight with this telehealth prescription service—see if it ...

The FDA now requires ADHD extended-release drug labels to warn of weight loss risks in children under 6, urging monitoring ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.